About

Oak Hill Bio Holdings Ltd (formerly known as Oak Hill Bio Ltd) was founded in 2021 to acquire and develop outstanding rare disease therapeutics deprioritized by big pharma. Oak Hill Bio Holdings is developing OHB-607, a replacement therapy designed to prevent complications of prematurity in extremely preterm infants. OHB-607 is currently in a phase 2b study.
‍
Oak Hill Bio Holdings also established and is a significant shareholder of OHB Pediatrics Ltd (operating under the trading name Oak Hill Bio). OHB Pediatrics' lead program is rugonersen (OHB-724), an investigational oligonucleotide entering Phase 3 for the treatment of Angelman syndrome, a devastating neurodevelopmental disorder with no approved disease-modifying therapies. For more information about OHB Pediatrics Ltd, please visit www.oakhillbio.com